Biodistribution and dosimetry for combined [
225Ac
Dosimetry
PSMA
Prostate cancer
SPECT
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
04
10
2022
accepted:
22
12
2022
pubmed:
12
1
2023
medline:
23
3
2023
entrez:
11
1
2023
Statut:
ppublish
Résumé
Quantitative SPECT for patient-specific dosimetry is a valuable tool in the scope of radionuclide therapy, although its clinical application for Eight prostate cancer patients (1000 MBq/8 MBq [ Kidney (r = 0.96, p < 0.01) and lesion (r = 0.94, p < 0.01) SUV for [ Quantitative low-count SPECT imaging of the peak at 440 keV during [
Identifiants
pubmed: 36629878
doi: 10.1007/s00259-022-06092-1
pii: 10.1007/s00259-022-06092-1
pmc: PMC10027798
doi:
Substances chimiques
Dipeptides
0
Heterocyclic Compounds, 1-Ring
0
Isotopes
0
Prostate-Specific Antigen
EC 3.4.21.77
Radiopharmaceuticals
0
Lutetium-177
BRH40Y9V1Q
Actinium-225
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1280-1290Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : 02NUK065C
Organisme : Deutsche Forschungsgemeinschaft
ID : GRK 2274
Organisme : Deutsche Forschungsgemeinschaft
ID : EXC 2145 SyNergy - ID 390857198
Informations de copyright
© 2023. The Author(s).
Références
Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
pubmed: 25220842
doi: 10.1002/ijc.29210
Kratochwil C, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59(5):795–802.
pubmed: 29326358
doi: 10.2967/jnumed.117.203539
Sathekge M, et al. Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy. J Nucl Med. 2020;61(1):62–9.
pubmed: 31101746
doi: 10.2967/jnumed.119.229229
Zacherl MJ, et al. First clinical results for PSMA-targeted α-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients. J Nucl Med. 2021;62(5):669–74.
pubmed: 33008928
doi: 10.2967/jnumed.120.251017
Rosar F, et al. Molecular imaging and biochemical response assessment after a single cycle of [225Ac] Ac-PSMA-617/[177Lu] Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu] Lu-PSMA-617 monotherapy. Theranostics. 2021;11(9):4050.
pubmed: 33754047
pmcid: 7977444
doi: 10.7150/thno.56211
Rahbar K, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85–90.
pubmed: 27765862
doi: 10.2967/jnumed.116.183194
Ahmadzadehfar H, et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu] Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2017;44(9):1448–54.
pubmed: 28488028
doi: 10.1007/s00259-017-3716-2
Khreish F, et al. 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47(3):721–8.
pubmed: 31758224
doi: 10.1007/s00259-019-04612-0
Dewaraja YK, et al. MIRD pamphlet no. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med. 2012;53(8):1310–25.
pubmed: 22743252
doi: 10.2967/jnumed.111.100123
Ljungberg M, et al. MIRD pamphlet no 26: joint EANM/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57(1):151–62.
pubmed: 26471692
doi: 10.2967/jnumed.115.159012
Robertson AK, et al. Multi-isotope SPECT imaging of the 225Ac decay chain: feasibility studies. Phys Med Biol. 2017;62(11):4406.
pubmed: 28362640
doi: 10.1088/1361-6560/aa6a99
Chun SY, Fessler JA, Dewaraja YK. Correction for collimator-detector response in SPECT using point spread function template. IEEE Trans Med Imaging. 2012;32(2):295–305.
pubmed: 23086521
pmcid: 3619230
doi: 10.1109/TMI.2012.2225441
Kratochwil C, et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41(11):2106–19.
pubmed: 25070685
pmcid: 4525192
doi: 10.1007/s00259-014-2857-9
Cordier D, et al. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8, Met (O2) 11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging. 2010;37(7):1335–44.
pubmed: 20157707
doi: 10.1007/s00259-010-1385-5
Sgouros G, et al. Pharmacokinetics and dosimetry of an α-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med. 1999;40(11):1935–46.
pubmed: 10565792
Usmani S, et al. 225Ac prostate-specific membrane antigen posttherapy α imaging. Clin Nucl Med. 2019;44:401–3.
pubmed: 30932973
doi: 10.1097/RLU.0000000000002525
Vatsa R, et al. 225Ac-PSMA-617 radioligand posttherapy imaging in metastatic castrate-resistant prostate cancer patient using 3 photopeaks. Clin Nucl Med. 2020;45(6):437–8.
pubmed: 32366786
doi: 10.1097/RLU.0000000000003031
Delker A, et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(1):42–51.
pubmed: 26318602
doi: 10.1007/s00259-015-3174-7
Ljungberg M, Strand SE, King MA, editors. The SIMIND Monte Carlo program. In: Monte Carlo calculations in nuclear medicine: applications in diagnostic imaging. 2nd ed. CRC Press; 2012. https://doi.org/10.1201/b13073 .
Jackson PA, et al. Radiation dosimetry in 177Lu-PSMA-617 therapy using a single posttreatment SPECT/CT scan: a novel methodology to generate time-and tissue-specific dose factors. J Nucl Med. 2020;61(7):1030–6.
pubmed: 31806772
pmcid: 7383083
doi: 10.2967/jnumed.119.233411
Rinscheid A, et al. Influence of sampling schedules on [177 Lu] Lu-PSMA dosimetry. EJNMMI physics. 2020;7(1):1–14.
doi: 10.1186/s40658-020-00311-0
Hänscheid H, et al. Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days. J Nucl Med. 2018;59(1):75–81.
pubmed: 28588150
doi: 10.2967/jnumed.117.193706
Kurth J, et al. Streamlined schemes for dosimetry of 177Lu-labeled PSMA targeting radioligands in therapy of prostate cancer. Cancers. 2021;13(15):3884.
pubmed: 34359784
pmcid: 8345627
doi: 10.3390/cancers13153884
Sandström M, et al. Kidney dosimetry in 777 patients during 177Lu-DOTATATE therapy: aspects on extrapolations and measurement time points. EJNMMI physics. 2020;7(1):1–15.
doi: 10.1186/s40658-020-00339-2
Willowson KP, et al. Feasibility and accuracy of single time point imaging for renal dosimetry following 177 Lu-DOTATATE (‘Lutate’) therapy. EJNMMI physics. 2018;5(1):1–9.
doi: 10.1186/s40658-018-0232-9
Gosewisch A, et al. 3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT. EJNMMI Res. 2019;9(1):1–14.
doi: 10.1186/s13550-019-0548-z
Böhlen T, et al. The FLUKA code: developments and challenges for high energy and medical applications. Nucl Data Sheets. 2014;120:211–4.
doi: 10.1016/j.nds.2014.07.049
Ferrari A, et al. FLUKA: a multi-particle transport code (Program version 2005). CERN-2005-010/SLAC-R-773/INFN-TC-05-11/CERN-2005-10, CERN Yellow Reports: Monographs, Cern. 2005. https://doi.org/10.2172/877507 , https://doi.org/10.5170/CERN-2005-010 .
Brosch-Lenz J, et al. Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T. EJNMMI physics. 2021;8(1):1–17.
Sgouros G, et al. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51(2):311–28.
pubmed: 20080889
doi: 10.2967/jnumed.108.058651
Wolf PA, et al. Few-view single photon emission computed tomography (SPECT) reconstruction based on a blurred piecewise constant object model. Phys Med Biol. 2013;58(16):5629.
pubmed: 23892823
doi: 10.1088/0031-9155/58/16/5629
De Kruijff RM, Wolterbeek HT, Denkova AG. A critical review of alpha radionuclide therapy—how to deal with recoiling daughters? Pharmaceuticals. 2015;8(2):321–36.
pubmed: 26066613
pmcid: 4491664
doi: 10.3390/ph8020321
Feuerecker B, et al. Pretherapeutic comparative dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2022;63(6):833–9.
pubmed: 34531260
pmcid: 9157737
doi: 10.2967/jnumed.121.262671
Yusufi N, et al. Comparative preclinical biodistribution, dosimetry, and endoradiotherapy in metastatic castration-resistant prostate cancer using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T. J Nucl Med. 2021;62(8):1106–11.
pubmed: 33443072
doi: 10.2967/jnumed.120.254516
Kratochwil C, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58(10):1624–31.
pubmed: 28408529
doi: 10.2967/jnumed.117.191395
De Kruijff R, et al. The in vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier. Sci Rep. 2019;9(1):1–13.
doi: 10.1038/s41598-019-48298-8
Woodward J, et al. LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides. Bioconjug Chem. 2011;22(4):766–76.
pubmed: 21434681
doi: 10.1021/bc100574f
McLaughlin MF, et al. LnPO4 nanoparticles doped with Ac-225 and sequestered daughters for targeted alpha therapy. Cancer Biother Radiopharm. 2014;29(1):34–41.
pubmed: 24102173
Schwartz J, et al. Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys Med Biol. 2011;56(3):721.
pubmed: 21220845
pmcid: 3034478
doi: 10.1088/0031-9155/56/3/012